[IMRD therapy for patients with metastatic pancreas cancer].
Yamashita
Kaname
K
Department of Surgical Oncology, Cancer Research Institute, Kanazawa University.
Takahashi
Yutaka
Y
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000075202:Contraindications; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D020714:Maximum Tolerated Dose; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine